BioCryst Financial Statements From 2010 to 2024

BCRX Stock  USD 5.08  0.07  1.36%   
BioCryst Pharmaceuticals financial statements provide useful quarterly and yearly information to potential BioCryst Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioCryst Pharmaceuticals financial statements helps investors assess BioCryst Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioCryst Pharmaceuticals' valuation are summarized below:
Gross Profit
10.9 M
Profit Margin
(0.68)
Market Capitalization
B
Enterprise Value Revenue
4.5196
Revenue
331.4 M
We have found one hundred twenty available fundamental signals for BioCryst Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioCryst Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 113.7 M or Selling General Administrative of 209.6 M, as well as many exotic indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Operating Cycle of 1.8 K. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement BioCryst Pharmaceuticals' financial leverage analysis and stock options assessment as well as various BioCryst Pharmaceuticals Technical models . Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

BioCryst Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets542.8 M517 M239 M
Slightly volatile
Short and Long Term Debt Total891.1 M848.7 M240.5 M
Slightly volatile
Total Current Liabilities157.5 M150 M72.1 M
Slightly volatile
Property Plant And Equipment Net22 M21 MM
Slightly volatile
Accounts Payable21.9 M20.9 M10.6 M
Slightly volatile
Cash65.7 M112.4 M107.8 M
Slightly volatile
Non Current Assets Total24.6 M21 M25.3 M
Pretty Stable
Cash And Short Term Investments410.3 M390.8 M191.7 M
Slightly volatile
Common Stock Shares Outstanding201.8 M192.2 M106.2 M
Slightly volatile
Non Current Liabilities Total863.6 M822.5 M236.7 M
Slightly volatile
Other Current Assets20.5 M19.5 M10.5 M
Very volatile
Total LiabilitiesB972.5 M308 M
Slightly volatile
Property Plant And Equipment Gross20.1 M19.1 M8.3 M
Slightly volatile
Total Current Assets520.8 M496 M213.9 M
Slightly volatile
Short Term Debt27.5 M26.2 M25.1 M
Very volatile
Common Stock Total Equity2.2 M2.1 M1.2 M
Slightly volatile
Short Term Investments292.3 M278.3 M68.7 M
Slightly volatile
Common Stock2.2 M2.1 M1.2 M
Slightly volatile
Other Liabilities46.2 K48.6 K3.6 M
Slightly volatile
Current Deferred RevenueM1.1 M190.2 M
Slightly volatile
Property Plant Equipment18.6 M17.7 M8.1 M
Slightly volatile
Other Assets664.1 M632.5 M244.4 M
Slightly volatile
Net Receivables59.8 M57 M20.3 M
Slightly volatile
Long Term Debt Total164.3 M156.5 M63.5 M
Slightly volatile
Capital Surpluse745.7 M1.3 B720.8 M
Slightly volatile
Deferred Long Term Liabilities46.2 K48.6 K2.9 M
Slightly volatile
Short and Long Term Debt35.1 M34.5 M31.5 M
Slightly volatile
Capital Lease Obligations23 M13.9 M13.8 M
Slightly volatile
Net Invested Capital297 M355.7 M209.1 M
Slightly volatile
Net Working Capital252.2 M346 M147.4 M
Slightly volatile
Capital Stock1.9 M2.1 M1.4 M
Slightly volatile

BioCryst Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.7 M1.6 M
Slightly volatile
Selling General Administrative209.6 M199.7 M57.8 M
Slightly volatile
Total Revenue348 M331.4 M91.5 M
Slightly volatile
Other Operating Expenses456.9 M435.1 M172.6 M
Slightly volatile
Cost Of Revenue9.2 M6.3 M7.7 M
Pretty Stable
Total Operating Expenses450.2 M428.8 M169.7 M
Slightly volatile
Income Tax Expense325.5 K310 K4.8 M
Very volatile
Research Development225.7 M214.9 M108.8 M
Slightly volatile
Selling And Marketing Expenses18 M17.1 M8.1 M
Slightly volatile
Interest Income14.7 M14 M4.7 M
Slightly volatile
Reconciled Depreciation1.1 M1.6 M852.2 K
Slightly volatile

BioCryst Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow321.6 M306.2 M119.2 M
Slightly volatile
Depreciation970.6 K1.7 M736.2 K
Slightly volatile
Other Non Cash Items88.3 M84 M22.4 M
Slightly volatile
Capital Expenditures2.1 M2.2 M1.4 M
Pretty Stable
Total Cash From Financing Activities57.9 M32.5 M91 M
Slightly volatile
End Period Cash Flow66.1 M112.4 M108.5 M
Slightly volatile
Stock Based Compensation52.8 M55.6 M25.9 M
Pretty Stable
Net Borrowings64.6 M84 M51.3 M
Slightly volatile
Issuance Of Capital Stock324.9 K342 K45.5 M
Slightly volatile
Exchange Rate Changes56.8 K63.9 K69.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.33.473822.3551
Pretty Stable
Days Of Payables Outstanding1.1 K1.2 K4.4 K
Slightly volatile
Ebt Per Ebit2.072.18141.2466
Slightly volatile
Payables Turnover0.290.30231.3107
Slightly volatile
Cash Per Share2.132.03331.3319
Slightly volatile
Quick Ratio2.842.98522.6013
Pretty Stable
Dividend Paid And Capex Coverage Ratio41.6943.8842224
Slightly volatile
Net Income Per E B T1.051.00141.0731
Slightly volatile
Cash Ratio0.710.74971.5463
Very volatile
Days Of Sales Outstanding59.5962.72184.9 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.071.02281.0465
Very volatile
Current Ratio3.143.30673.5346
Pretty Stable
Fixed Asset Turnover9.4915.78618.1819
Slightly volatile
Capital Expenditure Coverage Ratio41.6943.8842224
Slightly volatile
Debt Ratio1.71.620.6668
Slightly volatile
Price Sales Ratio3.33.473822.3551
Pretty Stable
Receivables Turnover3.015.81944.148
Very volatile
Asset Turnover0.670.64110.3047
Slightly volatile

BioCryst Fundamental Market Drivers

Cash And Short Term Investments390.8 M

BioCryst Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioCryst Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include BioCryst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. BioCryst Pharmaceuticals investors use historical funamental indicators, such as BioCryst Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioCryst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in BioCryst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioCryst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioCryst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue1.1 MM
Total Revenue331.4 M348 M
Cost Of Revenue6.3 M9.2 M
Ebit Per Revenue(0.31)(0.33)

Pair Trading with BioCryst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioCryst Stock

  0.62MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.77MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against BioCryst Stock

  0.55MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.54MDWD Mediwound Downward RallyPairCorr
  0.45EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.41CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
1.724
Quarterly Revenue Growth
0.174
Return On Assets
(0.12)
Return On Equity
(19.25)
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.